Hard to Treat Diseases (OTCPK:HTDS) - Stock Price, News & Analysis

HTDS Stock Overview

Manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally.

HTDS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($6K)

Shares are highly illiquid

Hard to Treat Diseases Inc. Competitors

Acro Biomedical

OTCPK:ACBM

US$42.0k

BIMI Holdings

OTCPK:BIMI

US$174.5k

Lucira Health

OTCPK:LHDX.Q

US$4.2k

ETAO International

OTCPK:ETAO.F

US$1.5k

Price History & Performance

Summary of all time highs, changes and price drops for Hard to Treat Diseases
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	0%
1 Year Change	0%
33 Year Change	0%
5 Year Change	0%
Change since IPO	-99.96%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	HTDS	US Healthcare	US Market
7D	0%	0.2%	0.9%
1Y	0%	12.2%	32.4%

Return vs Industry: HTDS underperformed the US Healthcare industry which returned 9.7% over the past year.

Return vs Market: HTDS underperformed the US Market which returned 32.1% over the past year.

Price Volatility

Is HTDS's price volatile compared to industry and market?
HTDS volatility
HTDS Average Weekly Movement	n/a
Healthcare Industry Average Movement	7.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stable Share Price: HTDS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HTDS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	n/a	Terry Yuan	www.mellowhope.com

Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East.

Hard to Treat Diseases Inc. Fundamentals Summary

How do Hard to Treat Diseases's earnings and revenue compare to its market cap?
HTDS fundamental statistics
Market cap	US$5.82k
Earnings (TTM)	US$974.30k
Revenue (TTM)	US$6.16m

0.0x

P/E Ratio

0.0x

P/S Ratio

Is HTDS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HTDS income statement (TTM)
Revenue	US$6.16m
Cost of Revenue	US$4.38m
Gross Profit	US$1.78m
Other Expenses	US$808.52k
Earnings	US$974.30k

Last Reported Earnings

Sep 30, 2010

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did HTDS perform over the long term?

See historical performance and comparison